EZH2 and myelodysplastic syndrome: At the same time, several oncoproteins appear to inhibit EZH2 activity in MDS cells, such as splicing factor serine- and arginine-rich splicing factor 2 (SRSF2) mutations that induce abnormal EZH2 splicing and promote MDS development [25].